Baseline characteristics of anti-tumour necrosis factor (TNF)-treated patients with rheumatoid arthritis classified according to European League Against Rheumatism response criteria
| Test cohort | Validation cohort | ||||
|---|---|---|---|---|---|
| Patient characteristics | No response (n=13) | Good response (n=19) | No response (n=44) | Moderate response (n=30) | Good response (n=18) |
| Age (mean, range) | 58 (42–74) | 53 (22–83) | 53 (24–80) | 56 (25–81) | 53 (32–69) |
| Sex (F/M) | 11/2 | 13/6 | 38/6 | 26/4 | 14/4 |
| DAS28 pretreatment (median, SD, range) | 5.29±0.92 (3.87–6.79) | 4.87±0.65 (3.90–6.12) | 4.37±1.3* (1.3–7.6) | 5.89±1.4* (2.0–7.4) | 4.97±0.89 (3.4–6.8) |
| Anti-CCP positivity (n, %) | 10 (77) | 14 (74) | 28 (64) | 21 (70) | 10 (55.6) |
| TNF inhibitor | |||||
| Etanercept (n, %) | 7 (54) | 10 (53) | 24 (55) | 11 (37) | 8 (44) |
| Adalimumab (n, %) | 3 (23) | 3 (16) | 16 (36) | 11 (37) | 4 (22) |
| Infliximab (n, %) | 3 (23) | 6 (32) | 1 (2)*† | 6 (20)* | 3 (17)† |
| Certolizumab (n, %) | 0 | 0 | 3 (7) | 0‡ | 3 (17)‡ |
| Golimumab (n,%) | 0 | 0 | 0 | 2 (7) | 0 |
Differences were not statistically significant between groups, unless indicated.
*p<0.05 between moderate and no response groups in the validation cohort. †p<0.05 between good and no response groups in the validation cohort.
‡p<0.05 between moderate and good response groups in the validation cohort.
CCP, cyclic citrullinated peptide; DAS28, disease activity score 28.